We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

74 hedge funds and large institutions have $100M invested in Gyre Therapeutics in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $2.04M | Put options by funds: $1.02M

20% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 20

0% more funds holding

Funds holding: 74 → 74 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

25% less capital invested

Capital invested by funds: $135M → $100M (-$34.1M)

Holders
74
Holders Change
–
Holders Change %
0%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
24
Reduced
20
Closed
14
Calls
$2.04M
Puts
$1.02M
Net Calls
+$1.01M
Net Calls Change
+$4.36M

Top Buyers

1
DM
Deerfield Management
New York
+$3.09M
2
BIT
BlackRock Institutional Trust
California
+$1.5M
3
BC
Broadfin Capital
New York
+$1.5M
4
Goldman Sachs
Goldman Sachs
New York
+$1.1M
5
CCM
Camber Capital Management
Massachusetts
+$926K

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$11M
2
BFA
BlackRock Fund Advisors
California
-$1.99M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.79M
4
Millennium Management
Millennium Management
New York
-$1.17M
5
HVC
Healthcare Value Capital
New Jersey
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$543K – – –
Two Sigma Advisers
27
Two Sigma Advisers
New York
$497K -$78.8K -20 -12%
Two Sigma Investments
28
Two Sigma Investments
New York
$484K -$319K -81 -35%
BCM
29
Bridgeway Capital Management
Texas
$449K – – –
B
30
Bailard
California
$442K – – –
BIM
31
BlackRock Investment Management
Delaware
$399K -$7.88K -2 -2%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$339K -$7.88K -2 -2%
Morgan Stanley
33
Morgan Stanley
New York
$293K +$122K +31 +53%
TI
34
Turner Investments
Pennsylvania
$286K -$59.1K -15 -15%
Group One Trading
35
Group One Trading
Illinois
$243K +$221K +56 +311%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$209K – – –
CS
37
Credit Suisse
Switzerland
$205K +$146K +37 +142%
PPA
38
Parametric Portfolio Associates
Washington
$199K -$7.88K -2 -3%
TA
39
Teachers Advisors
New York
$196K +$35.5K +9 +18%
Invesco
40
Invesco
Georgia
$192K +$122K +31 +111%
PAM
41
Panagora Asset Management
Massachusetts
$169K – – –
RA
42
Royce & Associates
New York
$166K – – –
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$161K -$11.8K -3 -6%
BA
44
BlackRock Advisors
Delaware
$160K +$94.6K +24 +96%
OA
45
Oak Associates
Ohio
$160K +$193K +49 New
Charles Schwab
46
Charles Schwab
California
$154K – – –
SM
47
Sabby Management
Florida
$148K +$177K +45 New
State Board of Administration of Florida Retirement System
48
State Board of Administration of Florida Retirement System
Florida
$147K – – –
SIM
49
Spark Investment Management
New York
$147K +$11.8K +3 +7%
VRS
50
Virginia Retirement Systems
Virginia
$139K -$3.94K -1 -2%
1
2
3 4

GYRE Hedge Fund Activity: Q4 2013 in Review

74 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2013, worth a combined $100M — down 25% from $135M a quarter earlier.

Fund positioning in GYRE was balanced in Q4 2013: 14 funds opened new positions, 14 closed out, 24 added to existing stakes and 20 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $3.09M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $11M sold.

  • 74 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2013, unchanged from Q3 2013.
  • Funds reported $100M of Gyre Therapeutics stock for Q4 2013, down 25% quarter-over-quarter.
  • 14 funds opened new Gyre Therapeutics positions in Q4 2013 and 14 closed out, a net change of 0 holders.
  • The largest Gyre Therapeutics buyer in Q4 2013 was Deerfield Management, an estimated $3.09M added.
  • The largest Gyre Therapeutics seller in Q4 2013 was Baker Bros. Advisors, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2013.